close
To:

From:

Current Advances

Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association

Genzyme and Isis Pharmaceuticals Inc. announced that new two-year data from a phase 3 long-term extension study of KYNAMRO® (mipomersen sodium) injection were presented at a scientific session at the annual American Heart Association meeting in Chicago, IL. In the study, a retrospective analysis showed that heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH) patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events (MACE) from 25.72/1000 patient months (in the two years prior to KYNAMRO treatments) to 3.6/1000 patient months.

Please click here for the full release

Previously this fall, Isis announced the one-year data from the long-term extension study of KYNAMRO were presented at the European Society of Cardiology (ESC) Congress in Barcelona Spain. In this analysis HeFH and HoFH patients treated for one year with KYNAMRO experienced a reduction in MACE from 25.72/1000 patient months (in the two years prior to KYNAMRO® treatments) to 4.85/1000 patient months.

Please click here for the full release

About Isis

We know that sick people depend on us, and we have the technology to change the way diseases are treated.

Learn More

Mission & Values

Our mission is to provide antisense drugs to patients with significant unmet medical needs.

Learn More